Mesoblast reports $36M quarterly Ryoncil revenue, $115M for first full year

Mesoblast Limited reported financial and operating results for its fiscal fourth quarter ended June 30, 2026, in a filing dated July 30, 2026. Ryoncil net revenue for the fourth quarter was US$36 million.¹ Across the first full year following FDA approval, Ryoncil generated US$115 million in net revenue, of which US$66.5 million came in the second half.¹

The company's net operating cash spend for the full year totaled US$43.8 million, with US$13.4 million of that spent in the second half.¹ Mesoblast held US$103 million in cash as of June 30, 2026, after drawing US$50 million from an existing five-year facility to pay off all maturing debt.¹

On the clinical side, a registrational trial to expand Ryoncil's label into adult patients with steroid-refractory acute graft versus host disease has begun enrolling, with plans to activate up to 40 U.S. sites this year covering roughly 60% of the country's approximately 8,500 annual adult allogeneic bone marrow transplant patients.¹ Separately, the FDA cleared an Investigational New Drug application allowing Mesoblast to move directly into a registrational trial testing Ryoncil in ambulatory children aged 5 to 9 with Duchenne muscular dystrophy, a condition affecting about 15,000 children in the U.S.¹

For its other lead candidate, Mesoblast reached its target of enrolling at least 300 patients in the MSB-DR004 Phase 3 trial of rexlemestrocel-L for chronic low back pain tied to degenerative disc disease, with those patients to be tracked through a twelve-month primary endpoint measuring pain reduction versus placebo.¹ The company also received a Biologics License Application filing number from the FDA and requested a modular review for rexlemestrocel-L in preventing gastrointestinal bleeding linked to right ventricular dysfunction in end-stage heart failure patients using a left ventricular assist device.¹